| 史春生,姜波.康柏西普玻璃体腔注射联合黄斑格栅样激光光凝治疗视网膜分支静脉阻塞性黄斑水肿 22例[J].安徽医药,2020,24(2):296-300. |
| 康柏西普玻璃体腔注射联合黄斑格栅样激光光凝治疗视网膜分支静脉阻塞性黄斑水肿 22例 |
| Intravitreal injection of Conbercept combined with retinal laser photocoagulation for recurrent macular edema secondary to branch retinal vein occlusion |
| |
| DOI：10.3969/j.issn.1009?6469.2020.02.021 |
| 中文关键词: 黄斑水肿 视网膜静脉闭塞 激光凝固术 玻璃体内注射 康柏西普 |
| 英文关键词: Macular edema Retinal vein occlusion Laser coagulation Intravitreal injections Conbercept |
| 基金项目:安徽省卫生计生委科研计划项目( 2018SEYL025)；安徽省高校自然科学研究项目( 12925KJ2018B11) |
|
| 摘要点击次数: 2439 |
| 全文下载次数: 594 |
| 中文摘要: |
| 目的评估康柏西普玻璃体腔注射联合黄斑格栅样激光光凝对视网膜分支静脉阻塞( BRVO)继发黄斑水肿病人的最佳矫正视力( BCVA)和黄斑中心视网膜厚度( CMT)的改善情况。方法选取 2015年 12月至 2017年 12月安徽省第二人民医院收治的 BRVO继发黄斑水肿病人 41例，分为观察组 22例，对照组 19例，观察组采用康柏西普玻璃体腔注射联合黄斑格栅样激光光凝治疗，对照组单纯采用康柏西普玻璃体腔注射治疗。两组在治疗前和治疗开始后 1，3，6和 12个月分别收集 BCVA和光学相干断层扫描记录的 CMT，观察组在第一次或随后的康柏西普注射后，在黄斑水肿( CMT≤350 um)减轻后 15 d立即进行黄斑格栅样激光光凝治疗。在随访期间，如果在光学相干断层扫描中观察到持续性或复发性黄斑水肿，则每隔 1个月再次采用康柏西普玻璃体腔注射。结果观察组和对照组康柏西普玻璃体腔平均注射次数分别为 2.8次和 3.2次，观察组的平均注射次数明显低于对照组( P＜0.05)；与治疗前相比，治疗后 1、3、6和 12个月两组的 BCVA均明显提高( P＜0.05)，但两组间治疗治疗前后效果差异无统计学意义( P＞0.05)；与治疗前相比，治疗后 1、3、6和 12个月两组 CMT均明显下降( P＜0.05)，并且观察组的治疗效果优于对照组( P＜0.05)。结论康柏西普玻璃体腔注射联合黄斑格栅样激光光凝可有效提高视网膜分支静脉阻塞性黄斑水肿病人的视力，减少康柏西普玻璃体腔注药次数，优于单纯康柏西普玻璃体腔注射治疗。 |
| 英文摘要: |
| Objective To evaluate the improvement of best corrected visual acuity(BCVA)and macular central retinal thickness(CMT)in patients with macular edema secondary to retinal branch vein occlusion(BRVO)after intravitreal injection of Conber? cept combined with retinal laser photocoagulation.Methods Forty?one cases of macular edema with BRVO，who were admitted to Anhui No.2 Provincial People’s Hospital from December 2015 to December 2017，were assigned into study group(n＝22)and control group(n＝19).The study group was treated with laser photocoagulation combined with VEGF inhibitors，while the control group was treated with intravitreal Conbercept injection alone.BCVA and CMT recorded by optical coherence tomography were col?lected before treatment and at 1，3，6 and 12 months after treatment initiation.At the time of treatment，intraperitoneal injection of Conbercept was performed，and after 15 days，macular grid photocoagulation was performed.During the follow?up period，if persis? tent or recurrent macular edema was observed in the optical coherence tomography，Combercept was injected again every other month.Results The average number of injections of Combercept in the study group was significantly lower than that of the control group(2.8 vs.3.2；P＜0.05).At 1 month，3 months，6 months，and 12 months after treatment，the patients’BCVA was significantly improved in both groups(P＜0.05)，but there was no significant difference in therapeutic effect between the two groups(P＞0.05). At 1 month，3 months，6 months，and 12 months after treatment，CMT was significantly decreased in both groups(P＜0.05)，and the therapeutic effect in the study group was better than that in the control group(P＜0.05).Conclusion Intravitreal injection ofConbercept combined with macular grid photocoagulation can effectively improve the vision of patients with macular edema associat?ed with BRVO，reduce the number of injections in the vitreous cavity，which is better than intravitreal Conbercept injection alone. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
